CJC-1295 Extends Growth Hormone Pulse Duration and Increases IGF-1 Levels in Healthy Adults

CJC-1295's value isn't just in elevating growth hormone—it's in how it does it. Instead of a sharp spike and crash, it creates sustained, pulsatile GH release that mirrors your body's natural rhythm. This matters because pattern may be as important as total GH levels when it comes to recovery and longevity. Think of it like sleep: six hours of deep, continuous rest beats eight hours of fragmented sleep. The week-long duration also means less frequent dosing, which matters for protocol compliance. When paired with Ipamorelin (which amplifies each pulse), CJC-1295 creates a synergistic effect—you're not forcing pharmacological GH levels, you're restoring a more youthful secretion pattern. That's the difference between supplementing and optimizing.

CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH) that includes a Drug Affinity Complex (DAC) to extend its half-life. This 2006 study was part of its clinical development and established the pharmacology in humans. Previous GH therapies required daily or twice-daily injections and often caused supraphysiological GH levels; CJC-1295 was designed to create a more natural pattern. The study measured both GH and IGF-1 (the downstream mediator of GH's effects), confirming that the elevated GH was functionally active. While CJC-1295 never completed commercial development, the human data established its safety profile and unique kinetic properties. The compound has since become a research standard for studying sustained GH elevation, and its frequent pairing with Ipamorelin is based on sound pharmacological reasoning—one extends the pulse duration, the other amplifies the pulse amplitude.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults